Roche's seventh China deal this year is a $1.2B obesity pact with Rona Therapeutics

Roche is set to fork over up to $100 million in upfront and near-term milestone payments to license an asset in a red-hot field for obesity: ALK7 inhibition. The deal with RNA interference specialist Rona ...

endpoints.news ·1h ago

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Roche signs $1.16B obesity drug deal with China’s Rona Therapeutics seekingalpha.com

Read the original at endpoints.news →

Roche's seventh China deal this year is a $1.2B obesity pact with Rona Therapeutics

Also reported by 1 other outlet

More in Health & Medicine

South Africa: SA's Cancer Story | Amid the Many Challenges, There Are Also 'Major Wins' Such As That With Cervical Cancer

Ambry Genetics launches whole genome sequencing solution

Nigeria: Behind Child Suffering from Malnutrition - The Mental Struggle of Caregivers

When the Laboratory Comes to You: How SYNLAB’s Home Sample Collection experience is balancing convenience with quality

Qatar International Medical Devices and Healthcare Exhibition and Conference to open Wednesday

Syndax's lung disease ambitions for Niktimvo end with a Phase 2 failure